Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25519258 | 0.80 | GAA (0.33) | LMNASSTR4SMN1; SMN2 | |
| SCHEMBL9040917 | 0.76 | TSHR (0.44) | TSHRALDH1A1LMNANSD2HTT | |
| SCHEMBL25519260 | 0.75 | EPHX1 (0.36) | ALDH1A1LMNAMEN1KMT2ASSTR4 | |
| SCHEMBL25519241 | 0.73 | CHRM2 (0.34) | TSHRKDM4EMEN1KMT2APOLB | |
| SCHEMBL19220263 | 0.73 | CHRM2 (0.34) | TSHRKDM4EMEN1KMT2APOLB | |
| SCHEMBL25519261 | 0.70 | CDK2 (0.37) | TSHRALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL8061740 | 0.70 | TSHR (0.50) | TSHRALDH1A1LMNAHTTKDM4E | |
| SCHEMBL25519242 | 0.69 | GPR119 (0.38) | POLB | |
| SCHEMBL9039587 | 0.69 | HTT (0.57) | TSHRALDH1A1LMNANSD2HTT | |
| SCHEMBL25519266 | 0.68 | CNR2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655255-B2 | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein | SPH NO.1 BIOCHEMICAL & PHARMACEUTICAL CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655255-B2 | Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein | PNP, TYMP, MTAP | TSHR 4483/4885ALDH1A1 2974/4885LMNA 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.